Drug Profile


Alternative Names: Gd-DTPA-BMEA; MP 1177; OptiMARK

Latest Information Update: 24 Nov 2009

Price : $50

At a glance

  • Originator Mallinckrodt Medical
  • Class Contrast media; Organometallic compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Marketed CNS disorders; Liver disorders
  • No development reported Myocardial infarction

Most Recent Events

  • 20 Nov 2009 The CHMP of the European Medicines Agency makes recommendations to minimise the risk of nephrogenic systemic fibrosis
  • 18 Nov 2009 No development reported - Phase-II for diagnosis of Myocardial infarction in USA (IV)
  • 30 Sep 2004 Phase-II clinical trials in diagnosis of Myocardial infarction in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top